DESCOVY 200-25 MG TABLET

What it is

DESCOVY 200-25 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as emtricitabine and tenofovir alafenamide, under the trade name “DESCOVY”.

FDA gives its dosage form as tablet and its route as oral.

The labeler, the company named on the label, is Gilead Sciences, Inc.

FDA lists it under 2 Established Pharmacologic Classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $2,248.24 for 30 tablets (30 × $74.94147 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-06-29. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 2, the latest survey was within 2% of the current NADAC, so the NADAC was carried forward from the previous file.

The NADAC of all 2 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-06-29. The file is new; the price is not.

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

All 2 NDCs

• 61958-2002-01 · Gilead Sciences, Inc. · $74.94147 per EA · eff. 2026-06-29 filed carried forward
• 61958-2002-02 · Gilead Sciences, Inc. · $74.94147 per EA · eff. 2026-06-29 filed carried forward

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name emtricitabine and tenofovir alafenamide with DESCOVY 200-25 MG TABLET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-06-29 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $74.94147 per EA filed.

Of the 28 other products in FDA’s Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 11 have a higher middle NADAC price and 17 a lower one. The one in the middle is BARACLUDE 0.5 MG TABLET, at $44.18654 per EA filed (eff. 2025-11-19).

Of the 28 other products in FDA’s Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 11 have a higher middle NADAC price and 17 a lower one. The one in the middle is VIREAD 300 MG TABLET, at $40.6865 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-11-19, 2026-06-29, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $2,165.76 for 30 tablets, at an average of $72.19217 per EA in 2024 (2024-01-01 to 2024-12-31) for “Descovy” and “Emtricitabine/Tenofov Alafenam”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 238,782 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.